BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25251443)

  • 1. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
    Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
    Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues.
    Takadate T; Onogawa T; Fukuda T; Motoi F; Suzuki T; Fujii K; Kihara M; Mikami S; Bando Y; Maeda S; Ishida K; Minowa T; Hanagata N; Ohtsuka H; Katayose Y; Egawa S; Nishimura T; Unno M
    Int J Cancer; 2013 Mar; 132(6):1368-82. PubMed ID: 22915188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteome of formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma and lymph node metastases.
    Naidoo K; Jones R; Dmitrovic B; Wijesuriya N; Kocher H; Hart IR; Crnogorac-Jurcevic T
    J Pathol; 2012 Apr; 226(5):756-63. PubMed ID: 22081483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
    Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
    Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma.
    Higashi M; Yokoyama S; Yamamoto T; Goto Y; Kitazono I; Hiraki T; Taguchi H; Hashimoto S; Fukukura Y; Koriyama C; Mataki Y; Maemura K; Shinchi H; Jain M; Batra SK; Yonezawa S
    Pancreas; 2015 Jul; 44(5):728-34. PubMed ID: 25906442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.
    Nagao Y; Hisaoka M; Matsuyama A; Kanemitsu S; Hamada T; Fukuyama T; Nakano R; Uchiyama A; Kawamoto M; Yamaguchi K; Hashimoto H
    Mod Pathol; 2012 Jan; 25(1):112-21. PubMed ID: 21983937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
    Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
    Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma.
    Alhasan SF; Haugk B; Ogle LF; Beale GS; Long A; Burt AD; Tiniakos D; Televantou D; Coxon F; Newell DR; Charnley R; Reeves HL
    Br J Cancer; 2016 Sep; 115(7):797-804. PubMed ID: 27560551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
    Lenz J; Karasek P; Jarkovsky J; Muckova K; Dite P; Kala Z; Veselska R; Hermanova M
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):389-96. PubMed ID: 22187705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 accumulation confers prognostic information in resectable adenocarcinomas with ductal but not with intestinal differentiation in the pancreatic head.
    Bergan A; Gladhaug IP; Schjolberg A; Bergan AB; Clausen OP
    Int J Oncol; 2000 Nov; 17(5):921-6. PubMed ID: 11029493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.
    Kamphues C; Bova R; Bahra M; Klauschen F; Muckenhuber A; Sinn BV; Warth A; Goeppert B; Endris V; Neuhaus P; Weichert W; Stenzinger A
    Pancreas; 2015 Mar; 44(2):296-301. PubMed ID: 25423555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
    Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
    Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
    Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
    Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Zhou X; Wang X; Duan J; Sun W; Chen Z; Li Q; Ou Z; Jiang G; Ren X; Liu S
    Pathol Res Pract; 2019 Feb; 215(2):343-346. PubMed ID: 30583814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
    Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
    Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.